News

Details

Published: 28 October 2020

• portfolio-news

Nordic digital therapeutics company Sidekick Health has completed a $20 million oversubscribed Series A financing round led by Wellington Partners and Asabys Partners, through its fund SAHII, with participation by existing investors Novator and Frumtak Ventures.  

Details

Published: 27 July 2020

• portfolio-news

CARISMA Therapeutics today announced that the U.S. Food and Drug Administration (FDA) has cleared an investigational new drug (IND) application for the Company's lead product candidate, CT-0508, an anti-human epidermal growth factor receptor 2 (HER2) targeted chimeric antigen receptor macrophage (CAR-M). Under this IND, CARISMA intends to initiate its Phase 1, first-in-human, multi-center study in patients with recurrent or metastatic HER2 overexpressing solid tumors after failure of approved HER2 targeted agents. 

Details

Published: 02 July 2020

• portfolio-news

Immatics (NASDAQ: IMTX) today announced the completion of its business combination with Arya Sciences Acquisition Corp. (NASDAQ: ARYA), a special purpose acquisition company (SPAC) sponsored by Perceptive Advisors. Today, Immatics will commence trading its shares under the symbol “IMTX” and its warrants under the symbol “IMTXW” on the Nasdaq Capital Market. Proceeds from this transaction were approximately $253 million, which included funds held in Arya’s trust account and the common stock private investment in public equity (PIPE) financing contributed by a group of leading US healthcare institutional investors.